{"url_path":"/sec/cik-0001900520/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","accession_number":"0001213900-26-057605","cik":"0001900520","ticker":null,"issuer_name":"Lomond Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1900520/0001213900-26-057605-index.html","primary_entity_key":"0001900520","primary_entity_name":"Lomond Therapeutics Holdings, Inc."},"word_count":468,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13\nOR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n** **\n\n**For the quarterly period ended March 31, 2026**\n\n \n\nor\n\n \n\n☐ TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n** **\n\n**For the transition period from _______ to _______**\n\n \n\nCommission file number: **000-56377**\n\n** **\n\n**Lomond Therapeutics Holdings, Inc.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**Delaware**   **87-2959575**\n\n(State or other jurisdiction of\nincorporation or organization)   (I.R.S. Employer\nIdentification No.)\n\n \n\n**8 The Green Ste 8490**\n\n**Dover, Delaware**\n  **19901**\n\n(Address of principal executive offices)   (Zip Code)\n\n \n\n**(212) 739-6400**\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities Registered Pursuant to Section 12(b) of the Act: **None**\n\n \n\nSecurities Registered Pursuant to Section 12(g) of the Act:\n\n \n\n**Title of Each Class**   **Trading Symbol**   **Name of Each Exchange on Which Registered**\n\nCommon Stock, $0.0001 par value per share   N/A   N/A\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12\nmonths (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒\nNo ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒ Smaller reporting company ☒\n\n    Emerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs of May 14, 2026, the registrant had a total of 32,198,214 shares\nof its common stock, par value $0.0001 per share, issued and outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**LOMOND THERAPEUTICS HOLDINGS, INC.**\n\n** **\n\n**FORM 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH\n31, 2026**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n \n**Page**\n\n \n \n \n\n[Special Note Regarding Forward-Looking Statements and Other Information Contained in this Report](#a_001)\n \nii\n\n \n \n \n\nPART I - FINANCIAL INFORMATION"}